Specificity Study of Diagnostic for Chagas Disease



Status:Completed
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:4/21/2016
Start Date:July 2015

Use our guide to learn which trials are right for you!

Determination of Estimated Specificity of Chagas Detect Plus Rapid Tests

This study assesses the specificity of Chagas Detect™ Plus (CDP) rapid test versus standard
reference tests (e.g. RIPA or IFA) for Chagas diagnosis in the US.

The Chagas Detect™ Plus Rapid Test is a rapid immunochromotagraphic strip assay for the
qualitative detection of antibodies to Trypanosoma cruzi (T. cruzi) in human serum or whole
blood samples. Reactive assay results are presumptive evidence of Chagas infection.

This study will enroll males and females 18-70 years of age from areas non-endemic for
Chagas infection. A fingerprick blood sample and a venous blood sample (for processing to
serum) will be collected from each subject. Subject age, gender, and symptoms will be
recorded. For this study, samples will have no personally identifiable information.

CDP and reference tests will be performed by different operators who are laboratory staff
members. These staff members, blinded to each other's results, will evaluate the samples
from each method independently.


Inclusion Criteria:

1. Male and female subjects 18 to 70 years of age

2. Subjects must be able to answer questions concerning:

1. Clinical symptoms

2. Blood transfusions

3. Organ transplants

4. Travel or residence in Chagas endemic areas

Exclusion Criteria:

1. Any subject who knows that they have positive serology for Chagas disease

2. Subjects who are unable to understand verbal of written or oral language of the
consent, or require a legal authorized representative for consent.
We found this trial at
1
site
?
mi
from
Baltimore, MD
Click here to add this to my saved trials